AUTL

NASDAQ open

Autolus Therapeutics

0.96 USD
▼-0.02-2.37%
盘后 1.28 0.00%
2026-11-20
市值
$241.65M
市盈率
—
EPS
-0.96
股息率
—
52 周区间
0.95 – 2.58
成交量
298.58K
Beta
2.35
目标价
8.36
52W 低 0.9552W 高 2.58
价格走势

公司简介

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in ph...